Synthetic Biologics and Intrexon have commenced development of a monoclonal antibody (mAb) therapy, SYN-005, to treat pertussis, commonly known as whooping cough. To manage the rising number of pertussis cases, Synthetic Biologics intends ...
Tags: Synthetic Biologics, monoclonal antibody therapy, whooping cough
Synthetic Biologics has enterd into second worldwide exclusive channel collaboration with Intrexon to address unmet medical needs of infectious diseases. Synthetic Biologics leverages Intrexon's suite of proprietary technologies for the ...
Tags: Synthetic Biologics, infectious diseases, medical needs